Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 study
2Citations
The Endometrioid Borderline ovarian tumor (EBOT) is the third most common histological subtype of borderline ovarian tumors. Due to the low incidence of disease, literature is scanty about the prognosis and management of this entity. The aim of this study is to evaluate clinical, surgical characteristics and risk of recurrence in EBOT patients with the experience of the MITO group (Multicenter Italian Trials in Ovarian Cancer). Clinicopathological data from patients with EBOT were retrospectively collected. Descriptive statistics were used to characterize the patient population. Clinicopathological features and treatment variables were evaluated for association with relapse. Fifty-six patients were recruited for this study. Median age of the patient at diagnosis was 49 years (range 34-84). Nineteen women (34 %) had a previous history of endometriosis. Forty-nine (87 %) were with unilateral tumors. Radical surgery was performed for 36 patients and FSS for 20 patients (14 USO, 5 Cystectomy, 1 both procedures). Three patients (6,5 %) had concomitant endometrial cancer (EC) and 4 (8,5 %) had atypical endometrial hyperplasia. Median time to follow up was 89 months (range 3-202). No disease-specific death was observed. During follow up time, 4 patients developed recurrent disease. EBOT is characterized by a good prognosis. Most EBOT tumors are stage I and unilateral. FSS is feasible if performed by experienced surgeons. However, uterine curettage should be done in case of uterine preservation.